Updated as of May 8, 2020

1. Jakafi marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis ex-U.S. 2. Adults with intermediate or high-risk myelofibrosis  3. Adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 4. Adults and pediatric patients 12 years and older with steroid-refractory acute GVHD 5. Adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by an FDA-approved test 6. European rights to Iclusig licensed from ARIAD 7. Adults with chronic phase, accelerated phase, or blast phase CML who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation 8. Adults with Ph+ ALL who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation 9. Certain development programs conducted in collaboration with Novartis 10. In collaboration with MorphoSys 11. In collaboration with MacroGenics 12. In collaboration with Merus  13. Co-development with Calithera 14. Discovery collaboration with Agenus 15. Worldwide rights to baricitinib licensed to Lilly: approved in multiple territories globally for certain patients with moderate to severe rheumatoid arthritis 16. Worldwide rights to capmatinib licensed to Novartis; approved in the U.S. for adults with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test

The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.